Another prospective single-arm, single-center clinical trial reported the results of PD-1 inhibitor combination with albumin-bound paclitaxel, platinum, and fluorouracil for the treatment of LA HNSCC, reporting an ORR of 85.7% and a pCR rate of 42.9% (14). The gene discussed is ALB; the disease is head and neck squamous cell carcinoma.